What is it about?

The USA, Greece and Italy accounted for 80% of resistant cases. In one-third of isolates resistance was not associated with previous CAZ/AVI exposure. Moreover, 20% of the strains were colistin-resistant and 80% were ESBL-producers. The majority of infected patients had severe underlying diseases (39% cancer, 22% solid-organ transplantation), and 37% died. The abdomen, lung, and blood were the most involved infection sites. Infections by CAZ-AVI-resistant strains were mainly treated with combination therapy (85% of cases), with meropenem being the most common (65%) followed by tigecycline (30%), gentamicin (25%), colistin (25%) and fosfomycin (10%). Despite the emergence of resistance, 35% of patients received CAZ-AVI.

Featured Image

Read the Original

This page is a summary of: Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies, Journal of Global Antimicrobial Resistance, June 2021, Elsevier,
DOI: 10.1016/j.jgar.2021.04.001.
You can read the full text:

Read

Contributors

The following have contributed to this page